Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 3.7x - 4.1x | 3.9x |
| Historical Pb Multiple | 1.5x - 10.4x | 2.2x |
| Fair Value | €9.61 - €10.63 | €10.12 |
| Upside | -5.7% - 4.2% | -0.8% |
| Benchmarks | - | Full Ticker |
| BioMarin Pharmaceutical Inc. | - | NasdaqGS:BMRN |
| Ionis Pharmaceuticals, Inc. | - | NasdaqGS:IONS |
| Intellia Therapeutics, Inc. | - | NasdaqGM:NTLA |
| BioCryst Pharmaceuticals, Inc. | - | NasdaqGS:BCRX |
| CSL Limited | - | OTCPK:CMXH.F |
| KalVista Pharmaceuticals, Inc. | - | DB:4XC1 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| BMRN | IONS | NTLA | BCRX | CMXH.F | 4XC1 | |||
| NasdaqGS:BMRN | NasdaqGS:IONS | NasdaqGM:NTLA | NasdaqGS:BCRX | OTCPK:CMXH.F | DB:4XC1 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | 6.6% | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | 3.6% | NM- | ||
| Latest Twelve Months | 155.0% | -19.0% | -8.3% | 74.4% | 11.2% | -62.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 14.1% | -41.5% | -792.4% | -178.6% | 20.7% | -564.2% | ||
| Prior Fiscal Year | 6.9% | -46.5% | -1326.5% | -68.4% | 16.5% | NA | ||
| Latest Fiscal Year | 15.0% | -64.4% | -896.8% | -19.7% | 17.9% | NA | ||
| Latest Twelve Months | 17.8% | -63.9% | -1154.1% | -10.6% | 18.0% | NA | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 7.3% | -50.4% | -44.3% | -2566.1% | 21.9% | -60.4% | ||
| Prior Fiscal Year | 3.5% | -76.3% | -42.1% | NM | 14.5% | -53.7% | ||
| Latest Twelve Months | 9.6% | -118.6% | -57.9% | NM | 15.4% | -150.5% | ||
| Next Fiscal Year | 14.0% | -92.5% | -72.6% | -10.1% | 17.3% | -144.8% | ||
| Two Fiscal Years Forward | 15.1% | -458.1% | -279.2% | -30.8% | 17.5% | 359.0% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 3.8x | 7.4x | 15.6x | 4.5x | 5.1x | NA | ||
| Price / LTM EPS | 21.3x | -11.6x | -1.4x | -42.1x | 28.0x | -3.3x | ||
| Price / Book | 1.9x | 11.2x | 0.9x | -5.0x | 4.2x | 4.0x | ||
| Price / Fwd Book | 1.7x | 24.7x | 1.7x | -5.2x | 3.8x | 17.4x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -5.0x | 1.9x | 11.2x | |||||
| Historical P/B Ratio | 1.5x | 2.2x | 10.4x | |||||
| Selected P/B Multiple | 3.7x | 3.9x | 4.1x | |||||
| (x) Book Value | 145 | 145 | 145 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | BMRN | IONS | NTLA | BCRX | CMXH.F | 4XC1 | |
| Value of Common Equity | 11,136 | 5,333 | 712 | 2,249 | 73,680 | 576 | |
| (/) Shares Outstanding | 191.8 | 159.2 | 103.6 | 209.3 | 484.2 | 49.7 | |
| Implied Stock Price | 58.07 | 33.51 | 6.87 | 10.75 | 152.17 | 11.58 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.14 | |
| Implied Stock Price (Trading Cur) | 58.07 | 33.51 | 6.87 | 10.75 | 152.17 | 10.20 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.14 | |